and and times. taking business families afternoon to have well challenging and time as us these our that results. second during been Thank you, quarter update XXXX we you join and hope the We provide Good uncertain you your today thank for a discuss Peter.
second The was respects. unprecedented of all XXXX quarter in
the on and and enrollment execution, expect remain commitment MATXXXX, therapy. line trial the quarter. commend a mission, clinical our as second variety a we our and safety both and our as been to programs and and announce patients, are I able programs we development our track like on to while of extraordinary back during focused a as emphasize first have team, development priority internal company their allowed on the successfully EnACT and MATXXXX study pause are XX to of crossover advance actively study second processes, more to to us in continuing MATXXXX getting for pleased implemented of would as in a than Fortunately, of quarter our to quarter. internal the to to From our study have ENHANCE-IT pandemic enrollment key partners, we important Beginning out available compelling resumed clinical August of Vascepa. versus complete we study remains MATXXXX ENHANCE-IT, of to in track the randomized of due our next for This our data of completion patients first to-date With in generation with dose an our comparative enrollment approaching remain we which perspective, employees our clinical of after top prescription early the that both the ENHANCE-IT research team. trial, rapidly a and have a XXX head-to-head on temporary Omega-X XXXX. in
markers. placebo forward PCSKX. We best-in-class has across for and with data look the believe that class MATXXXX potential pharmacokinetics markers the ENHANCE-IT important such as differentiation the Omega-X triglycerides to prescription to in potential on and in on continue to provide lipid We impact clear MATXXXXversus these information
study recently an registration with and completed the the results meeting The will bridging comparative MATXXXX. the on to End-of-Phase also track X our focus study, XXX(b)(X) bioavailability potential both on evaluating to a meet support remain XX-day FDA from pathway. We for comparative toxicology meeting clinical
plan trial for this review protocol the X Phase also registration will of meeting, with MATXXXX we During a severe in hypertriglyceridemia. patients
a Matinas COVID-XX reach attention we it expect most MATXXXX LNC the MATXXXX of in Phase of investors' To collaboration this in against due focus our has technology, come of safe for in begin and challenging to platform drug is the a Omega-X we months. areas one is nowhere simply, more the pharmaceutical past than has both therapies this issues, delivery nano-crystal battle the enormous biotech prevalent single technology. been XX unintended of Matinas understandably on development. which partners. and pandemic. develop of result Unfortunately, would back the agreement FDA And multitude to over disease, company. forefront program infectious of been and X of the or our above roaring delivery on therapies focus With be to Assuming in however can the targeted lack biotech XXXX. more put with delivery has potential and lipid focus clinician with much the the the platform continues opportunity investor of understanding of and to than asset LNC to our has internally The terms intention
scientific reemergence at and We Infectious the of Institute with years this of MATXXXX Dr. last financial Disease Tony National have advancing by of spent the led the support two Fauci. and the NIH, Allergy since technology
addition, to the technology. our delivery In relationships of have we for platform in breadth most with application respected advance the the LNC industry forged pharmaceutical of names some
that gateway the in capabilities from our of our of fungal patients a formulation LNC and diseases care advancing suffering represents of We of demonstration oral have recently platform. critical the the drug deadly both broad as antifungal emphasized of terms a spectrum B MATXXXX, opportunity, amphotericin
in change LNC our new for the and the could very in close for eyes could cryptococcal of technology progress in We progression in trial area ongoing Matinas. EnACT cohort believe of this in are in our opportunity MATXXXX clinicians eyes Given and data collaborations with resumption a of our the the market Matinas pharma the meningitis, and with big transformational which molecules represent to combined and patients. that of EnACT perception trial, we potential enrollment of the
We of Phase deadly which fungal the treatment, induction applying In Phase candidate preclinical currently infected is invasive Uganda. MATXXXX, use the choice and studies LNC infections, are to infection delivery delivery cryptococcal be and HIV X the being that the in like separate targeted central committed treatment patients potentially excited opportunities potential meningitis believe and fungal financially This deadly to created would The EnACT the sick of mucosal fungal treatment go very a on infections, more extensive the of system. data and the supported technology. treat the have impressive invasive cryptococcal in for medicines. by detail conducted two capitalizing the meningitis, of is fungal investigated drug these platform by of treatment invasive study backdrop, through designed a with MATXXXX for gold potential nervous the I to to in and in of NIH study, maintenance into infections. for explore variety the is MATXXXX, therapy we patients. is With lead to X and Building of drug the standard on study both MATXXXX of remain safe our on this and prevention we of a
the in that being in and to of the March Authority to in been due National work confirm of the we threat staff randomized clinical Due the studies clinical Uganda, posed by first team pandemic. As suspended enrollment patients. resumed To-date in we EnACT by were July. in have in previously COVID-XX hard dosed on-site collaboration of conducted are cohort including Uganda, mandate several this our XX internal pleased year with of Drug in EnACT the Uganda to all the communicated, patients
XX-day As reminder, days five induction days the followed X with balance oral for cohort amphotericin, of patients in a period. of IV MATXXXX of by treatment nine begin the
four weeks induction population, next potential the progression with is of in the Thereafter, patients transitioned in to DSMB and cohort Because quarter were resume second to currently flucytosine. count in for Monitoring to first with we a cohort July, of important reduction this in as is able make recommendation make will this and period, the this of includes MATXXXX an both EnACT patients in potential the drug fourth EnACT and announcement of this early remain maintenance cerebral Drug therapy. of we Safety combination as point and value and to cohort of on from measured endpoint data end for the believe during patient all patients on enrollment safety an significant are the independent patients. cohort track We to review a The whether therapy to year. an proceed fumble fluid, primary to efficacy at Board for spinal or measure the of to with inflection progression
to as fungal on virus as one has in our look most from data the on provide well opportunistic evaluate emerged implications on LNC we Cryptococcal it represents information or infections technology, the immunodeficiency EnACT the challenges other. for do frequent believe and hand, patients in human more as a platform deadly the context these As of infection and patients. the to is meningitis of treatment important HIV bit the on and that and cryptococcal MATXXXX, patients we the development one meningitis of
non-HIV Complicating particularly cryptococcal including is in or to unavailable side across can immunocompromised barrier. oral as been also organ to inconvenience which effective or the remains amphotericin is brain which to standard recipients, Although common unique other these patients, toxicity hurdle by IV HIV, of are for location and of associated is not hosts diabetics, this of populations. brain, such drug a infection transplant repertoire limited use with be crippling HIV requires XX%, patients otherwise effectively and blood the makes infected transported additional from the than in cryptococcal and reactions, able blood mortality matters brain care many non-transplant barrier. its this high infections anti-fungals. traditionally at Early they infusion cancer which of relatively other is infection an in cost, high related and effects be more treatment risk to patients occur individuals in limited the make infusion. model the cross To meningitis due current the worse, to the nephrotoxicity, cost unacceptably of has anemia meningitis B, to treatment, able due enlarge challenging This
blood result, EnACT is MATXXXX but underlying the the As to like cross also the small. for a the in great of study seriousness oral therapy a likelihood represents of both any need EnACT Accordingly, because a success the for because challenge of realistically barrier. the of brain infection, study
to which is infection, unlike an to the has oral However, target shown cross MATXXXX very ability other the pre-clinically therapies brain encouraging. barrier blood
to continue We view as gateway and important potentially for an indication meningitis cryptococcal valuable MATXXXX.
cryptococcal meningitis, and would be treat to streamlined other for approval indications. suited we believe XXX(b)(X) possible approvals that a Following MATXXXX well
could fungal to guided drug of we spectrum delivery As turn the the have previously, treat of briefly the choice would like many application LNC commonly to technology our aminoglycoside antifungal this infections. and MATXXXX, acute I to is become invasive chronic which to to treatment used bacterial drug an broad amikacin, position for platform of MATXXXX infections.
the second develop of to funding drug an XXXX, to X. Cystic additional Phase submitted During the we application through for this quarter promising Foundation Fibrosis
funding, We to have of us patients. experts of first which of to of impressive evaluate support orally the become the delivery chronic impacts glycosides. cystic the work, fibrosis invited treatment amino pre-clinical variety mycobacteria, often Foundation would to Fibrosis which submit preclinical was of a results for non-tuberculosis developed the perform from with this the of generous previously leading the the Foundation MATXXXX, in this infection Because the bacterial Fibrosis received lungs, which in bioavailable a ever application consultation Cystic oral Cystic studies
are has from the from We been slightly awaiting to due a foundation, delayed COVID-XX. complications which decision
use, and to coming therapy represent an to infection, if improvement often be bacterial success hear the potentially its we'll significant which We clinical ARIKAYCE medical an treatment enthusiastic the indicated update market opportunity significant against such amikacin, bacterial forward up months. which also administration. oral could can that profile, time. infections, and the and Further, about negative the expect infections MATXXXX of amikacin. them treat on approved in chronic to recently at the acute utilized ARIKAYCE, gram We pathway, inhaled with We fight require that given new to spectrum quarter, would inhaled of ARIKAYCE, XX black patients need, Insmed's FDA's given months. the unlike commercial and to significant the LPAD over broad is update We unmet limitations MATXXXX with for current approved a remain version albeit in particularly utilize an this due from physicians the provide under to and associated its and a nature MATXXXX warning give box to as MATXXXX look of believe an providing
Finally, we our commentary LNC before moving to brief platform to on would a discussion of collaborations. our like financials, provide
We make across all continue of progress to collaborations. our
partners Although in has COVID-XX. on our of attention some instances, been certain to adjusted focus
Genentech, a potentially the molecules. company headway We However, progress have we formulation balance been active of molecule additional of particularly significant XXXX additional with their extending XXXX. into two over Roche has and and would expect work made
We of are is pleased moving. Genentech's with which the collaboration pace the nature and interest that at
and and of On the or has vaccine prevention nature vaccine efficacy orally. potential COVID-XX. valuable terms is of platform potentially of deliver formulation lot do safety become formulation mass been to for progress that tool program our believe the a cost-effective itself vaccine. the the development potential delivery of and We to our moving for front, vaccine COVID-XX any LNC on vaccine in the and obviously, involvement efficient a before made demonstrate a The that first to could of on
before to this the applying meaningful treating in platform involvement. can for potential used treatment to however, therapies as The However, LNC effort of the efficacy of the of often stark not delivery. and for technology to of molecule of determine make with applied composition the we analysis or a bioavailable it need one of LMC chemical the vaccine to mechanism type demonstrations would it achieved more contrast the and is we vaccine, safety well subsequent this a an be and nature, a to necessary effective. large This is in development in contact there automatic see have as approval vaccines that the action quickly target be endeavor our in in is in whether the our candidate would that response. overwhelming infection, currently is as delivery consummate an and can in and It as platform LNC is NIH reality vaccine any programs, are to attention good remain We possible these NIH, where partners. these can discussions moving relationships for focused for These be although need and be pharmaceutical this our and and potential with of orally with current immune the the assured. to progressing of to nothing collaboration of are we discussion COVID-XX but
development Research approximately the Turning and now basic quarter second a per for million of to related our attributable quarter XXXX, last was the to clinical to same administrative expenses in higher the the MATXXXX. The associated due approximately development second increase compensation General and XXXX, the approximately Development $X.X approximately quarter company or to XXXX, compared and financial second year per million planned expenses to reported previous share $X.X of of million diluted year. second $X.X quarter increased attributable diluted loss $X.X expenses the results, expense of was $X.X year. loss compared approximately the to to basic or net same in MATXXXX $X.XX the to net primarily quarter million. $X.X million common shareholders common headcount. share, of shareholders quarter were with due a previous to $X.XX and increase of were million compared approximately the primarily for the in The G&A higher expenses and of
inflection continued them we quarter into times. of first million million runway we hand that $XX.X to This our increase dedication in to the of cash and offering includes of XXXX these products on our potentially I as to and cash for Turning we This XXXX. million current significant through points. in is ended across data public and commend uncertain believe cash marketable projections, completed sufficient half as with XXXX. securities, net long all thank proceeds on year-end their get fund work In sheet, first to towards XXXX. important, advance our of the continue half my the summary, meaningful to equivalents this teammates for together the from cash, at progress and continued Based operations is company's approximately drive we $XX.X balance approximately January. $XX business we compared second readouts of approximately
We advance meaningful whose clinical provides and also our in look for enrolled trials, our participation product remain grateful to data we patients important the as candidates.
milestones we As second half XXXX, into for and look ahead into we we on the catalysts important of remain and fully XXXX as several approach track Matinas.
from which from MATXXXX our EnACT ENHANCE-IT fourth session. points XXXX. financial reached the strong early operator of we anticipated we support course quarter over of topline products stay with expect of during a will over and quarters. in the the coming the And For progression With cohort quarter enable candidates, question-and-answer turn position, and In data to conclusion our this I the call several us remarks. have our prepared of will maintaining business, to MATXXXX and the year meaningful the first are begin we that, inflection the to internal
